tbuckley/cabot-search huggingface dataset:
Hepatitis associated with ranitidine
Authors: David Jack, Robert N. Smith
Journal: JAMA (1984)

<h3>To the Editor.—</h3> You recently published a case report from Dr Proctor<sup>1</sup>about a patient in whom a hepatitis without jaundice developed two weeks after ranitidine therapy was started. When ranitidine treatment was stopped, the clinical and laboratory features resolved within a week. Dr Proctor commented that the illness might have been caused by an influenza vaccine given three days before symptoms began or by the ingestion of aspirin or acetaminophen but also thought that a causal connection with ranitidine was possible because of the temporal relationships between exposure to ranitidine and the onset and the resolution of symptoms. On the evidence presented, we cannot disagree with his analysis but wish that he had notified us of the case before its publication, and we reserve our final judgment until full details are available. Dr Proctor is, however, mistaken in quoting as supporting evidence McCarthy's<sup>2</sup>hypothesis that ranitidine might
Endocrine Influences on Fat and Carbohydrate Metabolism in Man: II. Effect of Sulfonylurea Derivatives on Abnormalities of Serum Nonesterified Fatty Acid and Blood Glucose Concentration in Diabetes Mellitus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mammograms in Women Age 40 to 49: Results of The Canadian Breast Cancer Screening Study
Journal: Annals of Internal Medicine (2002)

Summaries for Patients3 September 2002Mammograms in Women Age 40 to 49: Results of The Canadian Breast Cancer Screening StudySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Breast cancers are often found when a woman or her doctor feels a lump in the breast. Mammograms are special x-rays of the breast that can identify breast cancers before lumps are felt. The goal of screening mammograms is to identify breast cancers before they have spread. Recently, there has been much debate about whether mammograms decrease rates of death from breast cancer. The controversy is greatest for mammograms in women age 40 to 49 years. The Canadian Breast Cancer Screening study is a large study of screening ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “The Canadian National BreChanging ast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up. A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years.” It is in the 3 September 2002 issue of Annals of Internal Medicine (volume 137, pages 305-312). The authors are AB Miller, T To, CJ Baines, and C Wall.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Canadian National Breast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up: A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years Anthony B. Miller , Teresa To , Cornelia J. Baines , and Claus Wall The Canadian National Breast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up: A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years Anthony B. Miller , Teresa To , Cornelia J. Baines , and Claus Wall Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: I-28KeywordsAge groupsBreast cancerBreast cancer screeningCancer screeningDeath ratesMammographyMortality ePublished: 3 September 2002 Issue Published: 3 September 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effects of hypoxia on granulocytic-monocytic progenitors in rats. Role of bone marrow stroma
Authors: R Taneja, P Rameshwar, J Upperman, M T Wang, D H Livingston
Journal: American Journal of Hematology (2000)

Hemorrhagic shock leads to hypoxia and is associated with bone marrow (BM) failure. Hemorrhagic shock is also a predisposing factor in immune dysregulation. Since the BM is the major organ of immune cells in the adult, its failure following hemorrhagic shock may explain the increased susceptibility to infection. The in vitro evidence indicates that hypoxia mediates altered functions in BM stroma. Since similar hematopoietic alterations are reported in hypoxia and hemorrhagic shock, hypoxia alone could be a representative model to study BM responses during hemorrhagic shock. In this study, we use an animal model to dissect the hematopoietic effects of hypoxia. We subjected rats to hypoxia, and at days 1 and 5 post-hypoxia we determined the numbers of granulocytic-monocytic progenitors (CFU-GM) in the BM. We found significant increase (P < 0.05) in CFU-GM at day 1 and a downward trend by day 5. Enhanced BM cellularity could not explain the increase in CFU-GM by day 1. BM stromal cells mediated most of the stimulatory effects by hypoxia. CFU-GM was inversely proportional to bioactive TGF-beta and directly proportional to IL-1. Compared to normoxic rats, IL-6 production was suppressed in BM cells from hypoxic rats. The results show that hypoxia alone initiate a stimulatory response in CFU-GM progenitors. These effects are at least partially mediated through the BM stroma. In the absence of a second insult, CFU-GM reverts to baseline. The data also suggest that hypoxia mediates complex responses that include cytokine production. These results add to the current understanding of hematopoietic responses by hypoxia and adds to the mechanisms of immune dysfunctions following hemorrhagic shock.
Indoor Exposures to Fine Aerosols and Acid Gases
Authors: P. Koutrakis, M. Brauer, S. L. K. Briggs, B. P. Leaderer
Journal: Environmental Health Perspectives (1991)

Indoor exposures to aerosols and gases are associated with both indoor and outdoor air pollution sources. The identification of sources and the assessment of their relative contribution can be a complicated process due to a) the presence of numerous indoor sources, which can vary from building to building; b) the uncertainties associated with the estimation of the impact of outdoor sources on indoor air quality; c) the interactions between pollutants; and d) the importance of reactions between pollutants and indoor surfaces. It is well established that fine particles (diameter less than or equal to 2.5 microns) originating from outdoor sources such as automobiles, oil and coal combustion, incineration, and diverse industrial activities can penetrate into the indoor environment. Indoor/outdoor ratios, usually varying between 0.4 and 0.8, depend on parameters such as particle size and density, air exchange rate, and the surface-to-volume ratio of the indoor environment. Determining fine particle elemental composition makes it possible to identify the contribution of different outdoor sources. This paper focuses on the origin and the concentration of indoor aerosols and acid gases by highlighting the results from two indoor air quality studies.
High Perioperative Oxygen Fraction for Abdominal Surgery and Risk of Surgical Site Infection—Reply
Authors: Christian S. Meyhoff
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNRECOGNIZED INFECTIONS IN PRODUCTION OF CARRIERS OF PATHOGENIC ORGANISMS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High interest in medical uses of marijuana and synthetic analogues [new]
Authors: B. J. Montgomery
Journal: JAMA (1978)

Rumors of the therapeutic potential of marijuana have a long history: Some archeologists believe the Scythians used cannabis (corroborating an account by Herodotus) and that the drug may have been used in northeast Asia during the neolithic period about 6,000 years ago. Its medical properties even were recorded in China's<i>Pen Ts'oo Ching</i>, the oldest known pharmacopoeia. Several American scientists have studied<i>Cannabis sativa</i>and its therapeutically most promising constituent, Δ-9-tetrahydrocannabinol (THC). It has proved effective in reducing intraocular pressure in glaucoma and shows considerable promise as an antiemetic agent, especially in patients undergoing chemotherapy for cancer. It may also find use as an antianxiety agent, though this is somewhat controversial. But an increasingly popular notion among much of the biomedical community is that if a marijuana-like medication is ever marketed, it probably will be a synthetic analogue tailored to avoid some of the effects of the natural drug. The
SEPTICOPYEMIA, SIMULATING BUBONIC PEST, AND CAUSED BY AN ANAEROBIC BACILLUS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Modern Hospital, Chicago
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Definition of Death
Authors: JAMES L. BERNAT
Journal: Annals of Internal Medicine (1981)

Letters and Corrections1 November 1981Definition of DeathJAMES L. BERNAT, M.D., CHARLES M. CULVER, M.D., PH.D., BERNARD GERT, PH.D.JAMES L. BERNAT, M.D., CHARLES M. CULVER, M.D., PH.D., BERNARD GERT, PH.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-95-5-652_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Capron and Lynn (1) claim that there is no significant difference between a statute such as the Uniform Determination of Death Act, which presents "both cardiopulmonary and neurologic criteria with relegation of the unitary conception of death to the commentary," and a statute that "begins with a 'unitary' definition of death in terms of brain functions that is then converted into a 'binary' definition by further statutory provisions," such as those proposed by the Law Reform Commission of Canada (2) and ourselves (3). We believe that this claim fails to recognize the important difference between a criterion...References1. CAPRONLYNN AJ. Definition of death. Ann Intern Med. 1981;95:236-7. Letter. LinkGoogle Scholar2. . Criteria for the Determination of Death. Ottawa: Law Reform Commission of Canada; 1981 (Report no. 15). Google Scholar3. BERNATCULVERGERT JCB. On the definition and criterion of death. Ann Intern Med. 1981;94:389-94. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Dartmouth College and Dartmouth Medical School Hanover, NH 03755 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByConceptual Approach to Human Death on Neurological Grounds 1 November 1981Volume 95, Issue 5Page: 652-652KeywordsBrain Issue Published: 1 November 1981 PDF DownloadLoading ...
Medical Specialties
Authors: Janet M. Torpy, Robert M. Golub
Journal: JAMA (2011)

Medical SpecialtiesF uture physicians go to medical school after they complete college.Medical students learn about many different areas of medicine, including those designated as specialties.At the end of medical school, doctors choose the specialty in which they will have more education and eventually practice.Education in each specialty takes 3 to 7 years of a residency after medical school.Some medical specialties have subspecialties that require even more education and training.Since medical knowledge is so complex and advanced, most doctors limit their practices to their area of specialization.The September 7, 2011, issue of JAMA is a theme issue on medical education.This Patient Page is based on one previously published in the September 5, 2007, issue of JAMA. PRIMARY CARE SPECIALTIES• Family medicine (primary care of adults and children) • Internal medicine (primary care of adults) • Pediatrics (primary care of children) Doctors who practice in the primary care specialties focus on general care of the patient.They often coordinate the specialized care that a patient may receive from different medical specialists.Primary care physicians usually provide continuing care for patients over a long time.They are also concerned with preventing diseases and medical problems.
THE PATHOLOGICAL UNITY OF TABES AND GENERAL PARALYSIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>RAS</i> mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data.
Authors: George Kafatos, Kimberly Lowe, Sophie Jenkins-Anderson, Tamer Garawin, Zuzana Traugottová, Antonios Bilalis, Edit Molnár, Karolina Wieruszewska-Kowalczyk, Daniela Niepel, J. Han van Krieken
Journal: Journal of Clinical Oncology (2016)

513 Background: Guidelines for prescribing anti-EGFR therapy for metastatic colorectal cancer (mCRC) require prior testing to confirm RAS (exons 2, 3, 4 of KRAS and NRAS) wild-type status in Europe and the USA. There is limited published evidence reporting the prevalence of RAS mutations in patients with mCRC in a real-world setting. The aim of this study was to use data from a range of real-world sources to obtain RAS mutation prevalence estimates for different geographic regions. Methods: Aggregated RAS mutation prevalence data were collected from 13 sources, including individual pathology centers (n = 7), mCRC registries (n = 3), and Amgen-sponsored studies (n = 3). Data sources included in this study originated in Europe (n = 10), the Middle East (n = 2), and South America (n = 1). A meta-analysis of all collected data was carried out to investigate the effect of heterogeneity amongst the data sources and obtain pooled RAS prevalence estimates for each, using a mixed regression model. Results: Aggregate data from 4322 patients with mCRC were included in the pooled meta-analysis. The overall RAS mutation prevalence across all data sources was estimated to be 43.5% (95% CI: 41.5–45.5%). RAS mutation prevalence varied between data sources, ranging from low estimates of 33.7% (95% CI: 28.4–39.3%) for a Middle Eastern pathology dataset, and 34.6% (95% CI: 27.7–42.1%) for a Middle Eastern mCRC registry, to the highest estimates of 53.6% (95% CI: 43.2–63.8%) and 54.1% (95% CI: 51.7–56.5%) in two European pathology centers, in the Czech Republic and Poland, respectively. Conclusions: This is one of the first studies to carry out a large pooled analysis of RAS mutation prevalence, based on real-world data. There was a high degree of heterogeneity between the sources included, possibly due to the types of data source, patient selection criteria, geographic location, or differences in laboratory testing methods. The estimated RAS mutation prevalence reported here is lower than that in a recent pooled analysis of past clinical trials, which reported an overall prevalence of 55.5% (95% CI: 53.9–57.9%) (Peeters M, et al. Eur J Cancer 2015;51:1704–13). Further investigations are required to explain the disparity in these findings.